Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 19.30 and a fair value of HKD 30.13 [5]. Core Insights - The company has achieved significant growth in 2025, with a revenue of RMB 3.001 billion, representing a year-on-year increase of 16.65%. The net profit reached RMB 340 million, up 34.77%, and the attributable net profit was RMB 318 million, reflecting a 39.00% increase. The adjusted net profit was RMB 381 million, showing a growth of 40.97% [8]. - The strong performance is attributed to accelerated external expansion, including the acquisition of the Nair brand, which enhances market share, and sustained organic growth driven by high-margin business segments [8]. - The company operates three main business segments: beauty and health services, medical beauty services, and sub-health medical services, all of which have shown growth in revenue and profitability [8]. Financial Summary - Revenue projections for 2024 to 2028 are as follows: RMB 2.572 billion (2024), RMB 3.001 billion (2025), RMB 4.013 billion (2026), RMB 4.786 billion (2027), and RMB 5.644 billion (2028), with growth rates of 19.9%, 16.7%, 33.7%, 19.3%, and 17.9% respectively [4][12]. - The company's EBITDA is projected to grow from RMB 704 million in 2024 to RMB 1.311 billion in 2028, with a notable increase in net profit from RMB 228 million in 2024 to RMB 651 million in 2028 [4][12]. - The report highlights a significant improvement in profitability metrics, with ROE expected to rise from 24.2% in 2024 to 35.8% in 2028 [4][12]. Business Performance - The beauty and health services segment generated RMB 1.658 billion in 2025, up 14.88%, while medical beauty services and sub-health medical services achieved revenues of RMB 1.017 billion and RMB 326 million, respectively, with growth rates of 9.56% and 62.16% [8]. - The gross margins for these segments were reported at 41.88%, 55.87%, and 64.31%, respectively, indicating an upward trend in profitability [8]. Strategic Outlook - The company is positioned as a leader in the industry, with a strong brand portfolio including Meili Tianyuan, Nair, and Siyuanli, which collectively enhance its competitive advantage [8]. - The dual strategy of organic growth and external acquisitions is expected to drive sustained high growth in the coming years, supported by refined operational efficiencies and scale effects [8].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.36 [1] Core Insights - The company achieved a revenue of CNY 3.001 billion in 2025, representing a year-on-year increase of 16.7%, and a net profit attributable to shareholders of CNY 318 million, up 39.0%, which aligns with expectations [6] - The company continues to show strong fundamentals with a same-store sales growth of 6.9% and a robust cash flow of CNY 2.59 billion, reflecting a year-on-year increase of 41.6% [6] - The company is positioned as a leader in the beauty and health chain service sector, benefiting from a dual growth strategy of organic growth and acquisitions [6] Financial Performance - Revenue projections for 2026 and 2027 have been revised upwards to CNY 3.915 billion and CNY 4.315 billion, respectively, reflecting increases of 30.49% and 10.21% [10] - The net profit forecast for 2026 and 2027 has also been adjusted to CNY 415.26 million and CNY 533.94 million, indicating growth rates of 30.76% and 28.58% [10] - The company’s gross margin improved to 49.1% in 2025, up 2.8 percentage points year-on-year, driven by cost optimization and acquisitions [8] Business Segments - The beauty and wellness services segment generated revenue of CNY 1.658 billion in 2025, with a year-on-year growth of 14.9% [7] - The medical beauty services segment reported revenue of CNY 1.017 billion, reflecting a year-on-year increase of 9.6% [7] - The sub-health medical services segment saw significant growth, achieving revenue of CNY 326 million, up 62.2% year-on-year [7] Valuation Metrics - The company is projected to have a PE ratio of 19 times for 2026, reflecting its leading position in the beauty chain sector [10] - The expected dividend yield for 2026 is 4.41%, indicating a commitment to returning value to shareholders [5]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [5][6]. Core Insights - The company achieved a revenue of 3.001 billion RMB in 2025, representing a year-over-year growth of 16.65%, with an adjusted net profit of 381 million RMB, up 40.96% year-over-year [2]. - The company's growth is driven by both organic and external factors, with three main business segments contributing to revenue: beauty and wellness services, medical beauty services, and sub-health medical services [3][5]. - The gross margin for 2025 was 49.05%, an increase of 2.79 percentage points year-over-year, driven by cost optimization and a shift towards higher-margin consumer medical services [4]. Revenue Breakdown - Beauty and wellness services generated 1.658 billion RMB, up 14.88% year-over-year, with direct store sales contributing 1.512 billion RMB, reflecting a 15.82% increase due to increased customer traffic and active membership [3]. - Medical beauty services accounted for 1.017 billion RMB, growing 9.56% year-over-year, supported by the "Double Beauty + Double Wellness" business model [3]. - Sub-health medical services saw significant growth of 62.16%, reaching 326 million RMB, attributed to an expanding membership base and a diversified product service matrix [3]. Financial Metrics - The adjusted net profit margin for 2025 was 12.69%, an increase of 2.19 percentage points year-over-year, reflecting improved operational efficiency [4]. - The company plans to continue its growth strategy through a combination of internal development and acquisitions, with expected revenues of 4.008 billion RMB in 2026, representing a 33.6% increase [5][6]. Future Projections - Revenue forecasts for 2026-2028 are 4.008 billion RMB, 4.519 billion RMB, and 4.897 billion RMB, with respective growth rates of 33.6%, 12.8%, and 8.4% [6]. - Adjusted net profits are projected to be 500 million RMB, 600 million RMB, and 693 million RMB for the same period, with growth rates of 31.2%, 20.1%, and 15.5% [6].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.36 [1]. Core Insights - The company achieved a revenue of CNY 3.001 billion in 2025, representing a year-on-year increase of 16.7%, and a net profit attributable to shareholders of CNY 318 million, up 39.0%, which aligns with expectations [6]. - The company continues to show strong fundamentals, with same-store sales growth of 6.9% and a high dividend payout ratio, with a year-end dividend of HKD 0.72 per share [6]. - The company is positioned as a leader in the beauty and health chain service sector, benefiting from a "dual beauty + dual healthcare" strategy, and is expected to leverage high-end consumption recovery trends for mid-term growth [6][10]. Financial Performance - Revenue projections for 2026 and 2027 have been revised upwards to CNY 39.15 billion and CNY 43.15 billion, respectively, reflecting increases of 18.6% and 21.5% [10]. - The company’s gross margin improved to 49.1% in 2025, up 2.8 percentage points year-on-year, driven by cost optimization and acquisitions [8]. - Operating cash flow for 2025 reached CNY 1.0 billion, marking a 25.4% increase year-on-year, demonstrating strong cash generation capabilities [9]. Business Segments - The beauty and wellness services segment generated revenue of CNY 1.658 billion in 2025, up 14.9%, with direct and franchise income growing by 15.8% and 5.9%, respectively [7]. - The medical beauty services segment reported revenue of CNY 1.017 billion, a year-on-year increase of 9.6%, with significant growth in customer traffic and average spending [7]. - The sub-health medical services segment saw remarkable growth, achieving revenue of CNY 326 million, up 62.2%, contributing to 10.9% of total revenue [7]. Valuation Metrics - The company’s projected PE ratio for 2026 is set at 19 times, reflecting its leading position in the beauty chain sector and expected growth from both organic and acquisition strategies [10]. - The report indicates a projected EPS of CNY 1.76 for 2026, with a continued focus on enhancing profitability through operational efficiencies [10].

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company achieved rapid revenue and adjusted profit growth in 2025, completing the integration of Narier and announcing the acquisition of Siyuanli, indicating a strong outlook for market share expansion through both organic and external growth strategies [2][3] Financial Summary - Total revenue for 2025 is projected at 30.01 billion RMB, representing a year-on-year increase of 16.7% - Adjusted net profit for 2025 is expected to reach 3.81 billion RMB, up 41.0% year-on-year - Gross profit margin increased by 2.8 percentage points to 49.1%, with adjusted net profit margin rising by 2.2 percentage points to 12.7% - Operating cash flow for 2025 is forecasted at 9.99 billion RMB, a 25.4% increase year-on-year [4][9] Business Performance - The "Double Beauty + Double Health" model effectively enhances member value, with beauty and health services being the largest revenue sources, generating 16.58 billion RMB in 2025, a 14.9% increase, accounting for 55% of total revenue - The number of visitors to direct-operated stores reached 1.724 million, a 23.2% increase year-on-year, while active members grew by 11.8% to 146,400 - Medical beauty services generated 10.17 billion RMB, a 9.6% increase, with a gross margin improvement of 3.6 percentage points to 55.9% - Sub-health medical services saw revenue growth of 62.2% to 3.26 billion RMB, with a gross margin increase of 6.1 percentage points to 64.3% [9] Acquisition and Integration - The acquisition of Narier, the second-largest brand in the Chinese beauty industry, has shown positive integration results, with single-store revenue increasing from 5.75 million RMB pre-acquisition to 8.10 million RMB, and adjusted net profit margin rising from 6.5% to 10.5% - The company announced the acquisition of Siyuanli for 1.25 billion RMB, expected to close in January 2026, aiming to replicate the successful integration experience of Narier to achieve significant market share growth [9]

Core Viewpoint - The company reported a revenue of 3 billion yuan in 2025, representing a year-on-year growth of 16.7%, and a net profit attributable to shareholders of 320 million yuan, up 39.0% [4] Group 1: Financial Performance - In 2025, the company achieved an operating cash flow of 1 billion yuan, an increase of 25.4% year-on-year [4] - The first half of 2025 generated revenues of 1.46 billion yuan, a 28.2% increase, while the second half saw revenues of 1.54 billion yuan, a 7.5% increase [4] - The adjusted net profit for 2025 was 380 million yuan, reflecting a year-on-year growth of 41.0% [4] Group 2: Business Segments Performance - The beauty and health services segment generated 1.66 billion yuan, up 14.9%, while medical beauty services and sub-health medical services achieved revenues of 1.02 billion yuan and 330 million yuan, growing by 9.6% and 62.2% respectively [5] - In the first half of 2025, beauty and health services revenue was 810 million yuan, a 29.6% increase, while the second half saw a revenue of 850 million yuan, a 3.7% increase [5] - The medical beauty services segment had a customer flow of 102,000, a 13.1% increase, and an average annual spending of 28,000 yuan per active member, up 490 yuan [6] Group 3: Growth Strategies - The company is focusing on a "super brand + super chain + super digitalization" strategy to enhance its long-term development [9] - The company has made strategic acquisitions of the second-largest brand, Nairui'er, and the third-largest brand, Siyuanli, to strengthen its market position [9] - The company aims to leverage high-margin medical services and rapidly growing sub-health services to create synergistic effects within its business model [9] Group 4: Operational Metrics - The company had a total of 550 stores by the end of 2025, with a slight decrease of 4 stores year-on-year [7] - The number of direct-operated stores in beauty and health services increased by 13 to 252, while franchise stores decreased by 16 to 260 [7] - The gross profit margin improved by 2.8 percentage points to 49.1%, and the net profit margin increased by 1.7 percentage points to 10.6% [8]

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 31.21 based on a projected average PE of 15 times for 2026 [4][7]. Core Insights - The company has established itself as a leader in the beauty and healthcare industry in China, with over 700 stores and a diversified business model that includes beauty services, medical aesthetics, and health management [7][14]. - The domestic beauty industry is characterized by a fragmented market that is ripe for consolidation, with the company holding a market share of approximately 0.29% in the beauty services sector and 0.53% in medical aesthetics [7][38]. - The company's dual beauty and health model enhances operational efficiency and customer acquisition, supported by a strong digital infrastructure that improves service delivery and customer retention [7][30]. Financial Summary - Revenue is projected to grow from CNY 21.45 billion in 2023 to CNY 25.72 billion in 2024, with a CAGR of 12.79% from 2019 to 2024 [3][28]. - Adjusted net profit is expected to increase from CNY 2.52 billion in 2024 to CNY 3.8 billion in 2025, reflecting a growth rate of over 40% [3][28]. - The company’s gross margin is expected to stabilize and improve, with significant contributions from the health management services segment [30][34]. Business Model and Market Position - The company operates under a "dual beauty and dual health" model, which integrates beauty services with health management, creating a comprehensive service ecosystem [7][44]. - The beauty services segment accounts for over 50% of revenue, while medical aesthetics and health management services are steadily increasing their contribution [7][22]. - The company has a strong management team with extensive experience in the beauty industry, which supports its strategic initiatives and operational execution [17][20]. Industry Outlook - The beauty services market in China is projected to grow to CNY 640.2 billion by 2030, with a CAGR of 5.3% from 2024 to 2030, indicating a robust growth trajectory [38][39]. - The medical aesthetics market is expected to reach CNY 415.7 billion by 2030, with a CAGR of 15.5%, driven by increasing consumer acceptance of non-surgical procedures [53][54]. - The health management services sector is also anticipated to grow significantly, with a projected market size of CNY 29 billion by 2030, reflecting a CAGR of 16.2% [7][38].

Investment Rating - The report gives a "Buy" rating for the company based on its business layout and growth potential [6] Core Insights - The company, Meili Tianyuan, is a leader in the beauty and health sector, leveraging a "Double Beauty + Double Health" model to create a value closed loop and drive long-term growth through both organic and external expansion [3][5] - The beauty industry in China has significant growth potential, with Meili Tianyuan holding a prominent market position, particularly in the traditional beauty and non-surgical medical beauty segments [4][38] Company Overview - Meili Tianyuan has established itself as a leading player in the beauty and health management sector, focusing on high-end clientele and offering a comprehensive service system [10] - The company operates under multiple brands, including Meili Tianyuan, Beili Shi, Xiuker, and others, and has made strategic acquisitions to enhance its market presence [3][10] Beauty Industry - The traditional beauty market in China is projected to grow from CNY 403.2 billion in 2021 to CNY 640.2 billion by 2030, with a CAGR of 5.3% [4][38] - The non-surgical medical beauty market is expected to expand significantly, with a projected CAGR of 17.46% from CNY 97.7 billion in 2021 to CNY 415.7 billion by 2030 [4][48] Financial Analysis - The company's revenue grew from CNY 1.405 billion in 2019 to CNY 1.781 billion in 2021, with a net profit increase from CNY 147 million to CNY 208 million during the same period [3][20] - The revenue forecast for 2025-2027 is CNY 30.11 billion, CNY 40.16 billion, and CNY 45.63 billion, respectively, with net profits projected at CNY 3.36 billion, CNY 4.51 billion, and CNY 5.37 billion [6][20] Core Highlights - The "Double Beauty + Double Health" model effectively addresses customer needs and enhances loyalty through a complete service cycle, from acquisition to retention [5][64] - The company has a strong focus on digital operations and refined membership management to expand its customer base and drive steady growth across its business lines [5][64]

Core Viewpoint - Dongwu Securities initiates coverage on Meili Tianyuan Medical Health (02373) with a "Buy" rating, highlighting its unique "Double Beauty + Double Health" ecosystem, proven acquisition integration capabilities, and excellent operational efficiency, which are expected to drive significant growth in the industry [1] Group 1: Company Overview - The company, established in 1993, has developed a comprehensive beauty and health management service system that includes traditional beauty, medical beauty, and sub-health assessment and intervention [2] - It operates four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its market position through acquisitions of Nairui'er and Siyuanli, forming a synergistic ecosystem of "life beauty + medical beauty + traditional health + sub-health medical" [2] Group 2: Financial Performance - The company demonstrates strong growth resilience, with revenue increasing from 1.503 billion in 2020 to 2.572 billion in 2024, representing a compound annual growth rate (CAGR) of 11.3% [3] - In the first half of 2025, revenue accelerated to 1.459 billion, a year-on-year increase of 28.2% [3] - Net profit attributable to shareholders rose from 151 million in 2020 to 228 million in 2024, with a year-on-year growth of 34.9% in the first half of 2025, reaching 156 million [3] - Gross margin improved to 49.33% in the first half of 2025, while net margin optimized to 10.67%, reflecting effective cost control and an increase in high-margin business [3] - The company commits to a dividend payout ratio of no less than 50% of net profit attributable to shareholders over the next three years, indicating strong dividend levels [3] Group 3: Industry Outlook - The traditional beauty, light medical beauty, and sub-health sectors are expected to continue expanding, with projected market sizes of 640.2 billion, 415.7 billion, and 29 billion respectively by 2030 [4] - As young consumers increasingly prioritize standardized services and stable experiences, leading companies are expected to gain significant advantages, leading to higher market concentration [4] - The overlapping consumer base in traditional beauty and light medical beauty allows for effective cross-referrals, enhancing customer conversion rates [4] Group 4: Business Synergy and Growth Strategy - The company's core business model exhibits strong synergy, utilizing its extensive and trusted life beauty services as a front-end traffic source to efficiently convert to high-ticket medical beauty and sub-health services, with a cross-business conversion rate of 28.7% in 2024 [5] - The company employs a strategy of "directly operated stores as benchmarks, franchising for coverage," leading to rapid expansion of its store network, which is expected to reach 554 by the end of 2024 [5] - The company has a robust target selection system and post-acquisition digital integration capabilities, as evidenced by the significant improvement in net margin following the acquisition of Nairui'er, showcasing its strong integration and empowerment capabilities [5]

Summary of the Conference Call for 美丽田园 Company Overview - 美丽田园 is expanding rapidly through acquisitions, planning to acquire competitors like 奈瑞尔 and 思妍丽 in 2025, increasing total store count to 734 [2][3] - The company expects significant growth based on acquisitions, with current stock price being undervalued, presenting investment opportunities [2] Financial Performance - Projected total revenue for 2024 is approximately 2.6 billion yuan, with revenue contributions of 55% from beauty and health services, 34% from medical aesthetics, and 10% from sub-health medical services [2][4] - Expected revenue growth of 28% in 2025, reaching 1.46 billion yuan, with 思妍丽 contributing around 850 million yuan [2][4] - The company maintains a dividend payout ratio of over 50%, with a dividend yield of about 4% [2][8] Industry Insights - The health and beauty industry exceeds 600 billion yuan, with traditional beauty market around 400 billion yuan and light medical aesthetics market at approximately 200 billion yuan, though growth rates are slowing [2][6] - The competitive landscape is fragmented, with leading players holding less than 1% market share, indicating potential for consolidation [6][7] - High closure rates of single institutions (around 20% annually) provide acquisition opportunities for leading companies [7] Growth Strategies - 美丽田园 is transitioning from direct sales and franchise models to a merger and acquisition strategy, leveraging customer resources from traditional beauty services to enhance profitability in medical aesthetics and sub-health services [3][4] - The company aims to combine beauty and medical aesthetics to achieve synergies and reduce costs amid rising customer acquisition costs and declining net profit margins in the industry [7] Future Outlook - Positive performance expectations for the next three years, with potential for revenue to double [8][9] - The company is actively preparing for acquisitions and expanding its franchise business, which is expected to grow alongside existing direct sales [9] - The sub-health business has shown significant growth, with a year-on-year increase nearing 100% in 2024 and maintaining similar growth in the first half of 2025 [9][10] Market Performance - In the life beauty segment, the company has achieved over 25% growth through internal growth and acquisitions [10] - In medical aesthetics, the focus on high-end customized services has stabilized the customer base and increased spending among existing customers [10] - The sub-health sector is expanding rapidly, with specific projects like women's care showing a year-on-year growth rate of 300% [10] Investment Value - 美丽田园 is characterized by low valuation and high growth potential, with a stable business model that exhibits economic resilience [11] - Future catalysts for growth include the pace of acquisition expansion and the stability of core traditional business operations [11]